Seroquel Approvable Letter

AstraZeneca PLC
30 October 2003


Stock Exchange Announcement


ASTRAZENECA RECEIVES FDA APPROVABLE LETTER FOR SEROQUELTM (QUETIAPINE FUMARATE)
                                    TABLETS
                              IN TREATMENT OF MANIA


AstraZeneca today announced that it has received an approvable letter from the
U.S. Food and Drug Administration (FDA) in response to its Supplemental New Drug
Applications (sNDAs) for the use of SEROQUEL as both an adjunct and monotherapy
for the treatment of manic episodes associated with bipolar disorder.  The
company is working closely with the FDA to supply information and to finalize
labelling.


                                     -Ends-

30th October, 2003



Media Enquiries:
Chris Major, [phone]


Investor Enquiries:

Mina Blair-Robinson, [phone]
Jonathan Hunt, [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange